In Situ Liquid-Liquid Phase Separation of Peptides Into Droplets Targeting Membraneless Organelles for Enhanced Cancer Chemotherapy.

IF 27.4 1区 材料科学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Weishu Wang,Hao Wang,Zeyu Zhang,Xin Liu,Binbin Hu,Feng Tian,Zhou Ye,Linqi Shi,Zhilin Yu
{"title":"In Situ Liquid-Liquid Phase Separation of Peptides Into Droplets Targeting Membraneless Organelles for Enhanced Cancer Chemotherapy.","authors":"Weishu Wang,Hao Wang,Zeyu Zhang,Xin Liu,Binbin Hu,Feng Tian,Zhou Ye,Linqi Shi,Zhilin Yu","doi":"10.1002/adma.202420399","DOIUrl":null,"url":null,"abstract":"Liquid-liquid phase separation (LLPS) of proteins and nucleic acids into membraneless organelles (MLOs) plays a critical role in sustaining fundamental physiological processes. However, creating artificial coacervate droplets in living cells from exogenous molecules and modulating the functions of MLOs remain challenging. To address this concern, here we reported enzyme-induced in situ phase separation of peptides into droplets targeting MLO stress granule (SG) for enhanced cancer chemotherapy. The peptide YSO4F containing two sulfated tyrosine residues undergoes sulfatase-responsive LLPS into droplets. Cellular studies confirm in situ phase separation of YSO4F selectively in sulfatase-overexpressing cancer cells. By integrating with appropriate ligands, the in situ-formed droplets d-YF-LSG coacervate with SGs driven by association between the ligand with SG key component protein G3BP2. Mechanistic studies illustrate that the in situ-formed droplets enhance the cytotoxicity of sorafenib via activating caspase-dependent apoptosis. Furthermore, animal experiments confirm that administration of the in situ-formed droplets with sorafenib significantly inhibits tumor growth in murine models bearing tumors, accompanied by an excellent biosafety profile. The findings in this study elucidate an innovative approach for in situ formulation of coacervate droplets within tumor cells and a new material for targeting membraneless organelles, thus providing a promising new strategy for disease organelle-targeted therapy in the future.","PeriodicalId":114,"journal":{"name":"Advanced Materials","volume":"33 1","pages":"e2420399"},"PeriodicalIF":27.4000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Materials","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1002/adma.202420399","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Liquid-liquid phase separation (LLPS) of proteins and nucleic acids into membraneless organelles (MLOs) plays a critical role in sustaining fundamental physiological processes. However, creating artificial coacervate droplets in living cells from exogenous molecules and modulating the functions of MLOs remain challenging. To address this concern, here we reported enzyme-induced in situ phase separation of peptides into droplets targeting MLO stress granule (SG) for enhanced cancer chemotherapy. The peptide YSO4F containing two sulfated tyrosine residues undergoes sulfatase-responsive LLPS into droplets. Cellular studies confirm in situ phase separation of YSO4F selectively in sulfatase-overexpressing cancer cells. By integrating with appropriate ligands, the in situ-formed droplets d-YF-LSG coacervate with SGs driven by association between the ligand with SG key component protein G3BP2. Mechanistic studies illustrate that the in situ-formed droplets enhance the cytotoxicity of sorafenib via activating caspase-dependent apoptosis. Furthermore, animal experiments confirm that administration of the in situ-formed droplets with sorafenib significantly inhibits tumor growth in murine models bearing tumors, accompanied by an excellent biosafety profile. The findings in this study elucidate an innovative approach for in situ formulation of coacervate droplets within tumor cells and a new material for targeting membraneless organelles, thus providing a promising new strategy for disease organelle-targeted therapy in the future.
靶向无膜细胞器的多肽液滴原位液-液相分离技术用于强化肿瘤化疗。
蛋白质和核酸的液液相分离(LLPS)进入无膜细胞器(MLOs)在维持基本生理过程中起着至关重要的作用。然而,利用外源分子在活细胞中制造人工凝聚液滴并调节MLOs的功能仍然具有挑战性。为了解决这一问题,我们报道了酶诱导的多肽原位相分离成靶向MLO应激颗粒(SG)的液滴,以增强癌症化疗。含有两个硫酸盐酪氨酸残基的肽YSO4F经历硫酸盐酶反应的LLPS成液滴。细胞研究证实,在过表达硫酸盐酶的癌细胞中选择性地原位相分离了YSO4F。通过与合适的配体结合,原位形成的液滴d-YF-LSG通过配体与SG关键成分蛋白G3BP2的结合驱动与SGs凝聚。机制研究表明,原位形成的液滴通过激活caspase依赖性细胞凋亡来增强索拉非尼的细胞毒性。此外,动物实验证实,在携带肿瘤的小鼠模型中,原位形成的液滴与索拉非尼一起施用可显著抑制肿瘤生长,并具有良好的生物安全性。本研究结果阐明了一种在肿瘤细胞内原位形成凝聚液滴的创新方法和靶向无膜细胞器的新材料,从而为未来的疾病细胞器靶向治疗提供了一种有希望的新策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advanced Materials
Advanced Materials 工程技术-材料科学:综合
CiteScore
43.00
自引率
4.10%
发文量
2182
审稿时长
2 months
期刊介绍: Advanced Materials, one of the world's most prestigious journals and the foundation of the Advanced portfolio, is the home of choice for best-in-class materials science for more than 30 years. Following this fast-growing and interdisciplinary field, we are considering and publishing the most important discoveries on any and all materials from materials scientists, chemists, physicists, engineers as well as health and life scientists and bringing you the latest results and trends in modern materials-related research every week.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信